Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Frontline KEYTRUDA In Gastroesophageal Cancer: Patients In Immunotherapy Arm Had Significantly Lower Side Effects.
Author: Editor
Danny Rischin MD Of Peter MacCallum Cancer Centre Discusses Who Should Get Monotherapy Or Pembrolizumab Combo: Reasonable To Use Pembrolizumab Monotherapy In Patients That Have CPS Greater Than 20,
Danny Rischin MD Of Peter MacCallum Cancer Centre Discusses KEYNOTE-48 Trial: 882 Patients Were Enrolled In Under 2 Years, Primary Endpoint Is Overall Survival & PFS.
Danny Rischin MD Of Peter MacCallum Cancer Centre Discusses KEYNOTE-48 Trial Implications: Will Provide An Opportunity For Patients To Have Treatment In First Line.
Anders Rabbe CEO Of Isofol Medical Discusses Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS .
Anders Rabbe CEO Of Isofol Medical Discusses Arfolitixorin: Support From FDA, Doctors Are Excited About The Drug & How It Works.
Anders Rabbe CEO Of Isofol Medical Discusses Arfolitixorin: Increases Efficacy Of Standard Of Care Chemotherapy.
Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses TEDOPI: A Patented Combination Of 10 Neo-Epitopes. TEDOPI Is Being Evaluated In NSCLC After Checkpoint Inhibitor Failure.
Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses TEDOPI Trials: NSCLC Trial Results In 2020, Primary Endpoint Is Overall Survival, Pancreatic Cancer Trial Results In 2020-2021.
Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses OSE Immunotherapeutics: French Company Based In Paris Focusing On How To Prolong & Sustain Existing T-Cells Life.
Frederic Ors BS Of IMV, Inc. Discusses DeCidE1 study: Looking At Tumor Aggression After Treatment, Up To 30 Month Clinical Response.
Earn CME: https://naccme.com/program/7331 In this presentation from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Mojtaba Akhtari discusses a patient case to examine whether transplant, conventional therapy, or novel targeted is most appropriate for the MRD+ patient subset and in what conditions. © 2019 Imedex, an HMP Company
Frederic Ors BS Of IMV, Inc. Discusses DeCidE1 study Questions: Why Not Use This Treatment In Earlier Stage Or Even First Line.
Earn CME: https://naccme.com/program/7331 In this presentation from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Daniel A. Pollyea provides an update on the latest advances in the treatment of acute myeloid leukemia (AML). © 2019 Imedex, an HMP Company
Hannah Linden MD Of The University of Washington School of Medicine Discusses What We Specialize In: Multidisciplinary Approach, One Stop Opinion, Consulting With Providers, Prescreening To Know If Patients Eligible.
Hannah Linden MD Of The University of Washington School of Medicine Discusses Palbociclib & Alpelisib: Improved Survival Benefit In Younger Breast Cancer Patients Given Palbociclib.
Earn CME: https://naccme.com/program/7330 In this presentation from the ‘CLL in the Era of Targeted Therapy’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Richard R. Furman utilizes a case presentation to examine personalized management strategies for relapsed/refractory, high risk patients with CLL. © 2019 Imedex, an HMP Company
Hannah Linden MD Of The University of Washington School of Medicine Discusses Hired Expert In Molecular Imaging: Huge Opportunity To Bring More Experimental Tracers That Look At PARP & Progesterone Receptor Imaging.
Hannah Linden MD Of The University of Washington School of Medicine Discusses Estrogen Receptor Imaging: Specialty Diagnostic Test That Can Only Be Done At A Center That Can Synthesize The Tracer.
Earn CME: https://naccme.com/program/7330 In this presentation from the ‘CLL in the Era of Targeted Therapy’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Jacqueline C. Barrientos discusses therapeutic sequencing in CLL patients, with a focus on mono vs. combination therapy. © 2019 Imedex, an HMP Company
Earn CME: https://naccme.com/program/7330 In this presentation from the ‘CLL in the Era of Targeted Therapy’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Richard R. Furman discusses novel agents and treatment strategies for patients with chronic lymphocytic leukemia (CLL). © 2019 Imedex, an HMP Company
Earn CME: https://naccme.com/program/7329 In this presentation from the ‘Minimal Residual Disease (MRD) Testing in Multiple Myeloma’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Prashant Kapoor agues against using MRD as the primary treatment target for patients with multiple myeloma. © 2019 Imedex, an HMP Company
Earn CME: https://naccme.com/program/7329 In this presentation from the ‘Minimal Residual Disease (MRD) Testing in Multiple Myeloma’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Prashant Kapoor agues that MRD should be the treatment target for patients with multiple myeloma. © 2019 Imedex, an HMP Company
Jakob Lindberg CEO Of Oncopeptides Discusses Melflufen Study: Lengthy Time To Next Treatment, Significant Reduction In Bone Pain, Positive Feedback From FDA Regarding HORIZON Study
Jakob Lindberg CEO Of Oncopeptides Discusses How Is Melflufen Different: Its A Lipophilic Peptide-Conjugated Alkylator That Rapidly Delivers A Highly Cytotoxic Payload Into Myeloma Cells Through Peptidase Activity.
Isaac Israel CEO @isaac2199 Of Kitov Pharmaceuticals Discusses Targeting CEACAM1: Idea Is To Block CEACAM Connections & Doing So Gives An Immune Response.
Isaac Israel CEO @isaac2199 Of Kitov Pharmaceuticals Discusses NT-219: First-In-Class, Novel Small Molecule Designed To Overcome Cancer Drug Resistance.
Isaac Israel CEO @isaac2199 Of Kitov Pharmaceuticals Discusses CM-24 Monoclonal Antibody: Plan To Initiate A Clinical Trial In Combination With Nivolumab, Initially Selecting NSCLC Patients.
Douglas S. Hawkins MD Of The University of Washington School of Medicine Discusses Questions About Larotrectinib: Who Should Be Tested, How Long Should They Be Treated, What Agent To Use BACKROUND: TRK fusions involving NTRK1, NTRK2, and NTRK3 genes have been identified in a broad range of pediatric and adult malignancies. Larotrectinib, a highly-selective oral TRK inhibitor, was well tolerated and showed encouraging antitumor activity in 17 pediatric patients (pts) with TRK fusion cancer (Laetsch et al, Lancet Oncol 2018). Here, we present data on the clinical efficacy and safety of larotrectinib in 38 pediatric pts with TRK fusion cancer…
Douglas S. Hawkins MD Of The University of Washington School of Medicine Discusses Larotrectinib Efficacy & Safety In Pediatric TRK Fusion Cancer Patients: 94% Of The Children Treated With Larotrectinib Achieved A Response. BACKROUND: TRK fusions involving NTRK1, NTRK2, and NTRK3 genes have been identified in a broad range of pediatric and adult malignancies. Larotrectinib, a highly-selective oral TRK inhibitor, was well tolerated and showed encouraging antitumor activity in 17 pediatric patients (pts) with TRK fusion cancer (Laetsch et al, Lancet Oncol 2018). Here, we present data on the clinical efficacy and safety of larotrectinib in 38 pediatric pts with…
Douglas S. Hawkins MD Of The University of Washington School of Medicine Discusses How To Identify Patients With An NTRK Gene Fusion: Will Require A Very Broad Genomic Sequencing. BACKROUND: TRK fusions involving NTRK1, NTRK2, and NTRK3 genes have been identified in a broad range of pediatric and adult malignancies. Larotrectinib, a highly-selective oral TRK inhibitor, was well tolerated and showed encouraging antitumor activity in 17 pediatric patients (pts) with TRK fusion cancer (Laetsch et al, Lancet Oncol 2018). Here, we present data on the clinical efficacy and safety of larotrectinib in 38 pediatric pts with TRK fusion cancer from…
Alexander Guminski MD Of The University of Sydney Discusses Where Is Cemiplimab Best Placed: Deploying Early As A Stand Alone Or Potentially As A Neoadjuvant Treatment.
Alexander Guminski MD Of The University of Sydney Discusses Phase 2 Study Of Cemiplimab: Response Rate Of 49 Estimated PFS Is 18.5 Months, Estimated Median OS At 2 Years Is 70.
Hossein Borghaei DO, MS @HosseinBorghaei Of Fox Chase Cancer Center discusses Pembrolizumab Survival Data: Minority Of Patients Are Surviving Beyond 4-5 Years, Checkpoint Inhibitors Are Giving Treatment Options That We Never Had.
Hossein Borghaei DO, MS @HosseinBorghaei Of Fox Chase Cancer Center discusses Broadening Eligibility Criteria For Trials: A Lot Of Eligibility Criteria Is No Longer Necessary.
Daniel George MD @daniel_j_george Of Duke University Cancer Institute Discusses S-TRAC Study Data: Took 3 Years To Complete, Disease Free Survival Rate Improved By 24With 1 Year Of Adjuvant Sunitinib.
Daniel George MD @daniel_j_george Of Duke University Cancer Institute Discusses Disparity Associated With Our Patient Population: African Americans Make Up 14Of The Population, Disparity In Outcome Is Due To Access Of Healthcare & Treatments.
Daniel George MD @daniel_j_george Of Duke University Cancer Institute Discusses Adjuvant Therapy In RCC: Very Controversial But Needs Continual Development, Sunitinib Therapy Is A Reasonable Approach To Take.
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses Molecular Tumor Boards: An Increasingly Needed Service, Implementing Molecular Tumor Boards Will Be More Important Over Time.
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses Molecular Tumor Boards In Clinical Practice: Increasingly Needed, GENTleMEN Study Offers Men With Prostate Cancer The Opportunity To Get Web & Phone Based Genetic Testing.
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses How To Help Men With BRCA1 & BRCA2 Mutations: Now Have Precision Oncology Treatments & Trials To Screen Men Who Are At Risk.
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses GENTleMEN Study: www.Gentlemen.org, Get A Saliva Kit Mailed To You & Learn If You Carry Cancer Risk Mutations.
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses Critical Importance Of Cascade Testing: Family Members Need Appropriate Counseling & Testing.
Matthew Galsky, MD, Director of Genitourinary Medical Oncology At The Tisch Cancer Institute at Mount Sinai Discusses HCRN GU14-182: Randomized Double-Blind Phase II Study Of Maintenance Pembrolizumab VS Placebo After First-Line Chemotherapy In Patients with mUC. BACKROUND: Platinum-based chemotherapy for 1st-line treatment of pts with metastatic urothelial cancer (mUC) is typically administered for a fixed duration followed by observation until recurrence. PD-1 blockade with pembro improves survival of pts with mUC progressing despite platinum-based chemotherapy. We explored the potential benefit of earlier use of PD-1 blockade using a “switch maintenance” approach. METHODS: Pts with mUC achieving at least stable disease…
Matthew Galsky, MD, Director of Genitourinary Medical Oncology At The Tisch Cancer Institute at Mount Sinai Discusses HCRN GU14-182 Questions: OS Is The Endpoint Needed To See To Impact Practice, Phase 3 Study Will Answer Future Questions. BACKROUND: Platinum-based chemotherapy for 1st-line treatment of pts with metastatic urothelial cancer (mUC) is typically administered for a fixed duration followed by observation until recurrence. PD-1 blockade with pembro improves survival of pts with mUC progressing despite platinum-based chemotherapy. We explored the potential benefit of earlier use of PD-1 blockade using a “switch maintenance” approach. METHODS: Pts with mUC achieving at least stable…
Elizabeth Buchbinder MD Of DFCI Discusses SITC Advances In Cancer Immunotherapy: Great Opportunity For Clinicians To Learn About All The Different Aspects Of Immunotherapy.
Elizabeth Buchbinder MD Of DFCI Discusses Mucosal Melanoma: Rare Form Of Melanoma With Much Lower Mutational Burden.
David Andorsky MD Of US Oncology Research Discusses MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) Plus Rituximab (Rituxan) Followed By Maintenance Therapy In Relapsed/Refractory NHL.
David Anderson PhD Of VBI Vaccines Discusses VBI-1901 Vaccine: Two Different Components In The Vaccine gB & pp65 Delivered In A Particle Intradermally, Phase 1 Trial Started.
David Anderson PhD Of VBI Vaccines Discusses Early Stages Of VBI-1901 Vaccine: Demonstrate Safety First, Encouraged By Correlations, Need To Expand Data Set.